Mini Oral session 11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitorsPresentation Number11MOLecture Time08:25 - 08:30SpeakersM. Majem Tarruella (Barcelona, Spain). 31/1/2023
IMO an understated step up data release
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $337.6M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $244.5K | 1.043M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 392012 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 126850 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |